黑料网

Biography

Dr. Jan M. Keppel Hesselink, MD, PhD is professor of molecular pharmacology at the university of Witten/Herdecke (Germany). He was elected as Fellow of the Pharmaceutical Faculty in Medicine (FFPM) in the UK. He worked several years at Bayer AG in Germany as VP CNS and business head CNS. He was advisor R&D and business strategies to the Dutch Royal Acadamy of Science (KNAW). Currently he is a consultant for life science companies and investors, founder of the Chonic Pain Coalition and of the Institute for Neuropathic Pain. His current focus is topical analgesic cream development and endocannabinoids as analgesics.

Research Interest

Dr. Jan M. Keppel Hesselink current focus is topical analgesic cream development and endocannabinoids as analgesics.

Certificate

Global Speakers in the subject

Global Experts in the subject

Publications

The Value of Placebos to Individualize Pain Therapy via A New Singleblind Test Paradigm Identifying Responders on Topical Analgesic Interventions

Topical Phenytoin in Neuralgic Pain, Peripheral Modulation of Central Sensitization: Two Case Reports

Jan M Keppel Hesselink and David J Kopsky

Review Article: J Pain Relief 2017, 7:313

DOI:

Use of the Analgesic, Anti-inflammatory and Neuroprotectant SupplementPalmitoylethanolamide in the Tarsal Tunnel Syndrome

Jan MK Hesselink and David J Kopsky

Case Report: J Pain Relief 2016, 6:284

DOI:

Jan M Keppel Hesselink

Editorial: Clin Res Foot Ankle 2014, 3: e105

DOI: